We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

186 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more call options, than puts

Call options by funds: $7.03M | Put options by funds: $2.73M

62% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 29

11% more funds holding

Funds holding: 168 → 186 (+18)

7% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 55

0.57% more ownership

Funds ownership: 108.71% → 109.28% (+0.57%)

5% less capital invested

Capital invested by funds: $1.24B → $1.18B (-$61.9M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
186
Holders Change
+18
Holders Change %
+10.71%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
47
Increased
59
Reduced
55
Closed
29
Calls
$7.03M
Puts
$2.73M
Net Calls
+$4.3M
Net Calls Change
+$8.98M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$20.9M
2
SCM
Suvretta Capital Management
New York
+$19.2M
3
BlackRock
BlackRock
New York
+$17.8M
4
CS
Candriam SCA
Luxembourg
+$11.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.21M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$33M
2
FCM
Farallon Capital Management
California
-$15.9M
3
B
Braidwell
Connecticut
-$12.9M
4
SC
Stempoint Capital
New York
-$11.2M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$8.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
26
Bain Capital Life Sciences Investors
Massachusetts
$9.59M -$8.87M -980,984 -49%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$9.37M +$7.15M +790,518 +365%
SC
28
Stempoint Capital
New York
$8.98M -$11.2M -1,240,507 -56%
Invesco
29
Invesco
Georgia
$8.72M +$590K +65,250 +7%
Charles Schwab
30
Charles Schwab
California
$7.92M +$910K +100,600 +13%
EP
31
Eversept Partners
New York
$7.79M +$7.58M +837,847 New
Goldman Sachs
32
Goldman Sachs
New York
$7.51M +$7.33K +810 +0.1%
TSC
33
Two Seas Capital
New York
$7.09M -$426K -47,142 -6%
Northern Trust
34
Northern Trust
Illinois
$6.99M +$26.3K +2,905 +0.4%
N
35
Nuveen
North Carolina
$6.84M +$4.4M +486,856 +196%
TI
36
Trexquant Investment
Connecticut
$6.21M +$2.75M +304,390 +84%
Two Sigma Investments
37
Two Sigma Investments
New York
$5.9M +$1.36M +150,360 +31%
Prudential Financial
38
Prudential Financial
New Jersey
$5.33M -$1.36M -150,710 -21%
Bank of America
39
Bank of America
North Carolina
$5.27M -$2.56M -283,406 -33%
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$5.24M -$3.44M -380,296 -40%
Millennium Management
41
Millennium Management
New York
$4.77M +$1.21M +133,645 +35%
IC
42
Ikarian Capital
Texas
$4.55M -$904K -100,000 -17%
Two Sigma Advisers
43
Two Sigma Advisers
New York
$4.54M +$1.43M +157,700 +48%
Balyasny Asset Management
44
Balyasny Asset Management
Illinois
$4.07M -$3.11M -343,418 -44%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$3.63M +$724K +80,078 +26%
Lazard Asset Management
46
Lazard Asset Management
New York
$3.35M +$3.26M +359,997 New
Federated Hermes
47
Federated Hermes
Pennsylvania
$3.26M – – –
JAFL
48
Jay A. Fishman Ltd
Michigan
$3.22M +$1.11M +122,300 +55%
PP
49
PDT Partners
New York
$2.97M -$4.62K -511 -0.2%
UBS Group
50
UBS Group
Switzerland
$2.88M -$1.64M -181,106 -37%
1
2
3 4 5

ARQT Hedge Fund Activity: Q2 2024 in Review

186 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2024, worth a combined $1.18B — down 5% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ARQT positions and 29 closed out — a net gain of 18 holders — while 59 added to existing stakes and 55 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $20.9M. The largest seller was State Street, cutting an estimated $33M.

  • 186 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2024, up from 168 in Q1 2024.
  • Funds reported $1.18B of Arcutis Biotherapeutics stock for Q2 2024, down 5% quarter-over-quarter.
  • 47 funds opened new Arcutis Biotherapeutics positions in Q2 2024 and 29 closed out, a net change of +18 holders.
  • The largest Arcutis Biotherapeutics buyer in Q2 2024 was Rubric Capital Management (New York), an estimated $20.9M added.
  • The largest Arcutis Biotherapeutics seller in Q2 2024 was State Street, an estimated $33M sold.

Based on aggregated 13F filings for Q2 2024.